MGMT Promoter Methylation and Glioblastoma Prognosis: A Systematic Review and Meta-analysis
Authors:
- Yang ChenYCYang Chen
- Fulan HuFHFulan Hu
- Yiheng ZhouYZYiheng Zhou
- Wangyang ChenWCWangyang Chen
- Hongying ShaoHSHongying Shao
- Ying ZhangYZYing Zhang
- 1 May 2013
- journal article
- review article
- Published by Elsevier in Archives of Medical Research
- Vol. 44 (4) , 281-290
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- DNA methylation in glioblastoma: impact on gene expression and clinical outcomeBMC Genomics, 2010
- O 6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastomaInternational Journal of Clinical Oncology, 2010
- MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastomaNeuro-Oncology, 2009
- Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma PatientsClinical Cancer Research, 2009
- Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed GlioblastomaJournal of Clinical Oncology, 2009
- Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapyBritish Journal of Cancer, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003
- Review papers : The statistical basis of meta-analysisStatistical Methods in Medical Research, 1993